Last reviewed · How we verify
increased dosing interval of biological therapy
increased dosing interval of biological therapy is a Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved.
The drug, an increased dosing interval of biological therapy, is currently marketed by Rigshospitalet, Denmark. A key strength is the protection provided by the key composition patent, which expires in 2028. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | increased dosing interval of biological therapy |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Proactive TDM Versus Standard Use of Biologics in Psoriasis (PHASE4)
- NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PHASE1, PHASE2)
- Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps (PHASE4)
- Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (NA)
- Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (NA)
- An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A (PHASE3)
- The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex (PHASE4)
- Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- increased dosing interval of biological therapy CI brief — competitive landscape report
- increased dosing interval of biological therapy updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI